Who
James Loerop
Chief Business Officer
Company insider
Files Form 4 as: Chief Business Officer, Aclaris Therapeutics; EVP Business Development, Anika Therapeutics.
In numbers
- Trades disclosed
- 85
- Buys
- 1
- Sells
- 2
- Bought
- $100K
- Sold
- $103K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 8 Jul 2019
- Last trade
- 3 Feb 2026
- Last filed
- 6 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —20,875 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code F | $21K5,937 at $3.47 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,875 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,875 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —20,875 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code F | $21K5,937 at $3.47 | filing |
| 2 Feb 2026filed 6 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —97,700 at $0.00 | filing |
| 2 Feb 2026filed 6 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —341,900 at $0.00 | filing |
| 2 Feb 2026filed 6 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —97,700 at $0.00 | filing |
| 2 Feb 2026filed 6 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —341,900 at $0.00 | filing |
| 1 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,250 | filing |
| 1 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —7,500 | filing |
| 1 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —14,750 | filing |
| 1 Feb 2026filed 5 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,250 at $0.00 | filing |
| 1 Feb 2026filed 5 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Feb 2026filed 5 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,750 at $0.00 | filing |
| 1 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code F | $38K10,686 at $3.51 | filing |
| 1 Feb 2026filed 5 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,250 at $0.00 | filing |
| 1 Feb 2026filed 5 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Feb 2026filed 5 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,750 at $0.00 | filing |
News
Analyzing Anika Therapeutics (NASDAQ:ANIK) & ADMA Biologics (NASDAQ:ADMA)ANIK · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name James Loerop; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.